Mesolimbic and striatal dopamine receptor supersensitivity: Prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG)

Pauline Chiu, G. Rajakumar, Simon Chiu, Rodney L. Johnson, Ram K. Mishra

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Functional supersensitivity of mesolimbic and striatal dopamine receptors has been suggested to contribute to the pathogenesis of schizophrenia and tardive dyskinesia. Using the rodent model of chronic administration of the neuroleptic haloperidol, we investigated the possible desensitizing effects of a tripeptide structurally unrelated to dopamine agonists, L-prolyl-L-leucyl-glycinamide (PLG) on mesolimbic and striatal dopaminergic receptor supersensitivity. Administration of PLG either prior to or after chronic haloperidol, inhibited the supersensitivity of dopamine receptors. The results have implications for pharmacological intervention in preventing tardive dyskinesia and relapse psychosis of schizophrenia.

Original languageEnglish (US)
Pages (from-to)179-183
Number of pages5
JournalPeptides
Volume6
Issue number2
DOIs
StatePublished - 1985

Bibliographical note

Funding Information:
This study was supported by the Ontario Mental Health Foundation of Canada and the National Institute of Neurological and Communicative Disorders and Stroke, NIH, USA. We wish to thank Sara DeSilvio for skillfully typing the manuscript.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Keywords

  • Haloperidol
  • Mesolimbic and striatal dopamine receptors
  • PLG
  • Supersensitivity
  • Tardive dyskinesia

Fingerprint Dive into the research topics of 'Mesolimbic and striatal dopamine receptor supersensitivity: Prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG)'. Together they form a unique fingerprint.

Cite this